Genmab’s bispecific halves risk of death in first-line HNSCC
Genmab is going to approach global agencies based on the interim Phase III data for its bispecific in first-line HNSCC.
Therapy Area
Podcast: ESMO26: Major readouts from the 2026 congress
Lilly’s retatrutide beats Ozempic in head-to-head trial
IDWeek 2026: BNT163 poised to fulfil a substantial unmet need for genital herpes
ESMO26: US and FDA movements to improve oncology trials a positive signal
ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine
IDWeek 2026: meropenem-pilabactam successfully targets critical priority pathogens
ESMO26: The “paradigm-shifting” readouts in endometrial & ovarian cancer
